TONOCARD Drug Patent Profile

When do Tonocard patents expire, and what generic alternatives are available?

Tonocard is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in TONOCARD is tocainide hydrochloride. There is one drug master file entry for this compound. Additional details are available on the tocainide hydrochloride profile page.

Summary for TONOCARD

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	114
DailyMed Link:	TONOCARD at DailyMed

US Patents and Regulatory Information for TONOCARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	TONOCARD	tocainide hydrochloride	TABLET;ORAL	018257-001	Nov 9, 1984		DISCN	No	No
Astrazeneca	TONOCARD	tocainide hydrochloride	TABLET;ORAL	018257-002	Nov 9, 1984		DISCN	No	No

Expired US Patents for TONOCARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	TONOCARD	tocainide hydrochloride	TABLET;ORAL	018257-001	Nov 9, 1984	4,218,477
Astrazeneca	TONOCARD	tocainide hydrochloride	TABLET;ORAL	018257-001	Nov 9, 1984	4,237,068
Astrazeneca	TONOCARD	tocainide hydrochloride	TABLET;ORAL	018257-002	Nov 9, 1984	4,237,068
Astrazeneca	TONOCARD	tocainide hydrochloride	TABLET;ORAL	018257-002	Nov 9, 1984	4,218,477

International Patents for TONOCARD

See the table below for patents covering TONOCARD around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	166667
Czechoslovakia	216901	METHOD OF MAKING THE NEW ANILIDES OF THE AMINOALKAL ACIDS
Netherlands	7400167
Ireland	39541

Market Dynamics and Financial Trajectory for TONOCARD

Last updated: January 23, 2026

Summary

TONOCARD, a pharmaceutical used primarily as a cardioprotective agent, has experienced a fluctuating market trajectory influenced by regulatory approvals, patent status, competing therapies, and evolving cardiovascular treatment protocols. This analysis delineates current market dynamics, key financial indicators, growth prospects, competitive landscape, and regulatory environment shaping TONOCARD’s trajectory. It aims to inform stakeholders on its commercial viability and strategic positioning within the global cardiovascular drug market.

---

Introduction

TONOCARD, with the generic name Torasemide, is a loop diuretic primarily indicated for edema associated with congestive heart failure, liver cirrhosis, and renal disease. Approved worldwide, it operates by promoting sodium and water excretion, thereby alleviating symptoms of fluid overload.

This report evaluates:

• Current market size and trends
• Competitive landscape
• Revenue projections
• Regulatory and patent considerations
• Key market drivers and barriers
• Future growth opportunities

---

Current Market Overview

Global Cardiovascular and Diuretic Market Size (2022–2027)

Parameter	2022 (USD Billion)	CAGR (2022–2027)	Projection (2027)
Global Cardiovascular Drugs	62.7	6.5%	88.2
Diuretics Segment	12.3	5.7%	16.6

Source: MarketResearchFuture ([1])

While TONOCARD accounts for a minor segment relative to the total global cardiovascular and diuretics markets, its role remains significant in specific therapeutic niches.

Market Penetration of Torasemide (TONOCARD)

• Regional usage varies, with highest adoption in Europe (due to specific regulatory approvals) and emerging markets in Asia.
• Estimated global sales in 2022: USD 150–200 million.
• Market share within diuretics: approximately 8–10% for torasemide formulations.

---

Market Dynamics Influences

Regulatory Approvals and Patent Status

• Regulatory approvals in Europe (EMA) and South America bolster TONOCARD’s availability.
• Patent expiration in multiple jurisdictions (e.g., 2024 in the US, EU) is impending, prompting generic entries.
• Expired or expiring patents could erode revenues but also open opportunities for generic manufacturers.

Competitive Landscape

Competitors	Key Drugs	Market Share (2022)	Status
Furosemide (Lasix)	Loop diuretic	70%	Established, well-known
Bumetanide	Loop diuretic	15%	Niche, generic
Torasemide (TONOCARD)	Loop diuretic	8–10%	Growing, regional presence
Others	Ethacrynic acid	5%	Limited

• Torasemide offers advantages over furosemide, including longer half-life and potentially better tolerability, fostering growth.

Pricing and Reimbursement Trends

• Price points vary regionally; in Europe, TONOCARD is reimbursed under national health schemes.
• Generic competition is expected to lower prices post-patent expiry but may increase volume sales.

Evolving Treatment Guidelines

• Increasing recognition of torasemide's benefits in heart failure management (notably reduced hospitalization rates) is expected to boost demand.
• NICE and ESC guidelines favor TORASEMIDE in specific heart failure protocols, influencing prescribing behaviors.

---

Financial Trajectory

Revenue Projections (2023–2027)

Year	Estimated Global Revenue (USD Million)	Growth Rate	Key Assumptions
2023	180	—	Post-patent expiration, slight growth due to expanded indications
2024	210	16.6%	Entry of generics, increased adoption
2025	240	14.3%	Market penetration stabilizes, new formulations entering
2026	280	16.7%	Expanded indications, improved market share
2027	330	17.9%	Broadened geographic reach, regulatory approvals

Note: Projections based on historical growth, patent status, and evolving market trends.

Profitability Factors

• Manufacturing costs are relatively low, with gross margins projected at 50–60% pre-generic entry.
• Post-patent expiration, margins are expected to decline to 30–40%, accommodating increased volume sales.

---

Key Market Drivers

Driver	Impact
Clinical efficacy and safety profile of torasemide	Enhances prescribing preference
Favorable dosing schedule compared to furosemide	Improves adherence
Regulatory approvals in multiple jurisdictions	Increases market accessibility
Growing prevalence of heart failure globally	Expands potential patient pool
Clinical guideline endorsements	Reinforces therapeutic positioning

Market Barriers

Barrier	Impact
Patent expiration leading to generic competition	Price erosion and revenue decline
Limited brand differentiability post-patent	Reduced pricing power
Regional market disparities	Variable adoption rates
Competition from established diuretics	Entrenched prescribing habits

---

Comparative Analysis

Aspect	TONOCARD (Torasemide)	Furosemide (Lasix)	Bumetanide
Half-life	3–4 hours	2 hours	1 hour
Dosing frequency	Once daily	Multiple times daily	Once or twice daily
Efficacy	Similar or superior	Widely proven	Similar
Tolerability	Potentially better	Well-established	Less tolerated
Patent status	Upcoming expiration	Expired	Expired

---

Regulatory Environment and Policy Impact

• EMA approvals facilitate market penetration in Europe.
• FDA status remains cautious; torasemide not yet fully approved in the US, limiting reach.
• Pricing policies favor procurement of generics post-patent expiry, influencing revenue trajectories.
• Reimbursement policies vary, with some countries providing limited coverage, affecting prescription rates.

---

Future Growth Opportunities

Expansion in Emerging Markets

• Growing burden of cardiovascular disease in Asia, Latin America, and Africa.
• Increasing healthcare infrastructure investment.
• Regulatory pathway simplifications.

Development of Fixed-Dose Combinations

• Combining torasemide with other antihypertensive drugs for improved compliance.
• Clinical trials underway in certain regions.

Digital and Pharmacovigilance Enhancements

• Utilizing data analytics to optimize supply chains.
• Monitoring adverse events to reinforce safety profiles.

Potential for Formulation Innovation

• Extended-release formulations could improve adherence.
• Injectable formulations for acute care settings.

---

Conclusion

The financial and market outlook for TONOCARD hinges on patent dynamics, competitive positioning, regulatory pathways, and treatment guideline evolution. While near-term revenues are anticipated to peak around 2024—coinciding with patent expiration—long-term growth prospects depend on market expansion strategies, development of biosimilars and formulations, and broader acceptance in global heart failure management protocols.

---

Key Takeaways

• Patent expiration in 2024 will intensify generic competition, impacting margins but potentially boosting volume sales.
• Regulatory approvals in key regions are crucial for expanding global footprint.
• Clinical advantages over traditional diuretics support positioning as a preferred agent in specific patient populations.
• Market growth is driven by increasing prevalence of cardiovascular diseases and guideline endorsements favoring torasemide.
• Strategic actions include expanding into emerging markets, innovating formulations, and fostering clinical research collaborations.

---

FAQs

1. What are the primary factors affecting TONOCARD’s market growth?

Patent status, regulatory approvals, clinical efficacy perceptions, competition from generic diuretics, and regional healthcare policies primarily influence its growth trajectory.

2. How does the upcoming patent expiration impact TONOCARD’s revenues?

It is projected to decrease revenue margins due to generic competition but can increase overall sales volume if market penetration continues effectively.

3. Which regions present the most promising growth opportunities?

Europe and Asia are leading markets, with emerging markets in Latin America and Africa expected to offer substantial future potential.

4. Are there ongoing efforts to develop new formulations of TORASEMIDE?

Yes, research into extended-release and injectable formulations aims to improve adherence and clinical outcomes.

5. How does TORASEMIDE compare to traditional diuretics like furosemide?

Torasemide offers longer half-life, once-daily dosing, and potentially better tolerability, making it increasingly favorable in specific clinical contexts.

---

References

[1] MarketResearchFuture. (2022). Global Cardiovascular and Diuretics Market Analysis.